Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in MDS After HMA Failure
NCT03957876Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at Day 28. Started Jul 2019; status: terminated.
02
Drugs
cytarabine
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT03957876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957876.